RESEARCH STUDY

International urticaria guideline (2022)

2022
Review
High

One-line finding

Non-drowsy antihistamines are first-line for hives, with higher doses and omalizumab as next steps.

Plain-language summary

A large international panel of experts reviewed the evidence and agreed on how to define, classify, and treat hives (urticaria). They recommend starting with non-drowsy (second-generation) antihistamines, raising the dose if needed, and adding omalizumab for cases that do not respond. This guideline shapes how doctors treat hives worldwide.

Citation

Read the study